Format

Send to

Choose Destination
Pharmacology. 2019 Aug 30:1-12. doi: 10.1159/000502401. [Epub ahead of print]

Pharmacodynamic Effect of Ellagic Acid on Ameliorating Cerebral Ischemia/Reperfusion Injury.

Wang Y1,2, Wu Y3, Liang C2, Tan R4, Tan L5,6, Tan R3,1.

Author information

1
School of Materials Science and Engineering, Southwest Jiaotong University, Chengdu, China.
2
College of Medicine, Southwest Jiaotong University, Chengdu, China.
3
College of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China.
4
School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
5
College of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China, rafael0927@163.com.
6
School of Materials Science and Engineering, Southwest Jiaotong University, Chengdu, China, rafael0927@163.com.

Abstract

Cerebral ischemia/reperfusion (I/R) injury causes a larger population of disable patients and deaths annually. Three Tibetan prescriptions have been applied in alleviating the I/R injury for a 1,000 years. Interestingly, ellagic acid (EA) is one of the commonly dominated phytochemicals in these 3 prescriptions. Therefore, it is noteworthy to evaluate the association between the pharmacodynamics effects of EA and I/R injury alleviation. In this study, we reveal that the EA can effectively reduce the infarction area, and prevent the neuron from apoptosis and damage in permanent middle cerebral artery occlusion rat model. The results of the histopathological study indicate that alleviation of brain damage is positively correlated with the EA dose. Further by biochemical analysis, it indicates that the EA can alleviate the brain damage by the anti-inflammatory and anti-oxidative response mediated by EA. The upregulation of zonula occludens-1 and down-regulation of Aquaporin 4 and matrix metalloprotein 9 (MMP-9) in injured brain tissues after being treated with EA suggested that the reconstruction of brain-blood-barrier (BBB), which can further prevent the brain from further injury by the other xenobiotics. In addition, EA will not activate the coagulation factors XII to induce coagulation formation during the treatment process. Therefore, EA is a promising candidate oral drug for I/R injury therapy.

KEYWORDS:

Cerebral ischemia/reperfusion injury treatment; Ellagic acid; Histopathology; Pharmacology; Tibetan prescriptions

PMID:
31473749
DOI:
10.1159/000502401
Free full text

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center